Single acute-dose and repeat-doses toxicity of anti-HIV-1 PNA TAR-penetratin conjugate after intraperitoneal administration to mice

Oligonucleotides

Volumn 18, Issue 1, 2008, Pages 9-20

  Chaubey, Binay ^a   Tripathi, Snehlata ^a   Pandey, Virendra N ^a  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PENETRATIN; PEPTIDE NUCLEIC ACID; CARRIER PROTEIN;

AGILITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW BIOPSY; CONTROLLED STUDY; DIARRHEA; DRUG RESPONSE; DRUG TOLERANCE; GASTROINTESTINAL TOXICITY; INFLAMMATION; KIDNEY FUNCTION; LIVER FUNCTION; LIVER TOXICITY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; SPLEEN FUNCTION; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW; CHEMISTRY; DOSE RESPONSE; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; INTRAPERITONEAL DRUG ADMINISTRATION; KIDNEY; LIVER; LONG TERMINAL REPEAT; MASS SPECTROMETRY; PATHOLOGY; SPLEEN;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS 1; MUS;

ANIMALS; BONE MARROW; CARRIER PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HIV LONG TERMINAL REPEAT; HIV-1; INJECTIONS, INTRAPERITONEAL; KIDNEY; LIVER; MALE; MASS SPECTROMETRY; MICE; MICE, INBRED BALB C; PEPTIDE NUCLEIC ACIDS; SPLEEN;

EID: 44349162361     PISSN: 15454576     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.2007.0088     Document Type: Article

References (35)

1. AGARWAL, S., TEMSAMANI, J., GALBRAITH, W., and TANG, J. (1995). Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet. 28, 7-16.
2. ALDRIAN-HERRADA, G., DESARMENIEN, M.G., ORCEL, H., BOISSIN-AGASSE, L., MERY, J., BRUGIDOU, J., and RABIE, A. (1998). A peptide nucleic acid (PNA) is more rapidly internalized in cultured neurons when coupled to a retro-inverso delivery peptide. The antisense activity depresses the target mRNA and protein in magnocellular oxytocin neurons. Nucleic Acids Res. 26, 4910-4916.
3. BLACK, L.E., FARRELLY, J.G., CAVAGNARO, J.A., AHN, C.H., DEGEORGE, J.J., TAYLOR, A.S., DEFELICE, A.F., and JORDAN, A. (1994). Regulatory considerations for oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies. Antisense Res. Dev. 4, 299-301.
4. BOFFA, L.C., CUTRONA, G., CILLI, M., MARIANI, M.R., MATIS, S., PASTORINO, M., DAMONTE, G., MILLO, E., RONCELLA, S., and FERRARINI, M. (2005). Therapeutically promising PNA complementary to a regulatory sequence for c-myc: pharmacokinetics in an animal model of human Burkitt's lymphoma. Oligonucleotides 15, 85-93.
5. BOFFA, L.C., CUTRONA, G., CILLI, M., MATIS, S., DAMONTE, G., MARIANI, M.R., MILLO, E., MORONI, M., RONCELLA, S., FEDELI, F., and FERRARINI, M. (2007). Inhibition of Burkitt's lymphoma cells growth in SCID mice by a PNA specific for a regulatory sequence of the translocated c-myc. Cancer Gene Ther. 14, 220-226.
6. BRANDEN, L.J., MOHAMED, A.J., and SMITH, C.I. (1999). A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA. Nat. Biotechnol. 17, 784-787.
7. CHAUBEY, B., TRIPATHI, S., GANGULY, S., HARRIS, D., CASALE, R.A., and PANDEY, V.N. (2005). A PNA-transportan conjugate targeted to the TAR region of the HIV-1 genome exhibits both antiviral and virucidal properties. Virology 331, 418-428.
8. CHIARANTINI, L., CERASI, A., FRATERNALE, A., MILLO, E., BENATTI, U., SPARNACCI, K., LAUS, M., BALLESTRI, M., and TONDELLI, L. (2005). Comparison of novel delivery systems for antisense peptide nucleic acids. J. Control Release 109, 24-36.
9. CORNISH, K.G., IVERSEN, P., SMITH, L., ARNESON, M., and BAYEVER, E. (1993). Cardiovascular effects of a phosphorothioate oligonucleotide with sequence antisense to p53 in the conscious rhesus money. Pharmacol. Commun. 3, 239-247.
10. CUTRONA, G., BOFFA, L.C., MARIANI, M.R., MATIS, S., DAMONTE, G, MILLO, E., RONCELLA, S., and FERRARINI, M. (2007). The peptide nucleic acid targeted to a regulatory sequence of the translocated c-myc oncogene in Burkitt's lymphoma lacks immunogenicity: follow-up characterization of PNAEμ-NLS. Oligonucleotides 17, 146-150.
11. DELONG, R.K., NOLTING, A., FISHER, M., CHEN, Q., WICKSTROM, E., KLIGSHTEYN, M., DEMIRDJI, S., CARUTHERS, M., and JULIANO, R.L. (1997). Comparative pharmacokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleotides in nude mice. Antisense Nucleic Acid Drug Dev. 7, 71-77.
12. DEMIDOV, V.V., POTAMAN, V. N., FRANK-KAMENETSKIL, M. D., EGHLOM, M., BUCHARD, O, SONNICHSEN, S.H., and NIELSEN, P. E. (1994). Stability of peptide nucleic acids in human serum and cellular extracts. Biochem. Pharmacol. 48, 1310-1313.
13. HENRY, S.P., NOVOTNY, W., LEEDS, J., AULETTA, C., and KORNBRUST, D.J. (1997). Inhibition of coagulation by a phosphorothioate oligonucleotide. Antisense Nucleic Acid Drug Dev. 7, 503-510.
14. JANSEN, K., and RICHELSON, E. (2000). Detection of peptide nucleic acids in tissue extracts of treated animal by gel mobility shift assay. J. Biochem. Biophys. Methods 42, 31-34.
15. KAUSHIK, N., and PANDEY, V.N. (2002). PNA targeting the PBS and A-loop sequences of HIV-1 genome destabilizes packaged tRNA3(Lys) in the virions and inhibits HIV-1 replication. Virology 303, 297-308.
16. KAUSHIK, N., TALELE, T.T., MONEL, R., PALUMBO, P., and PANDEY, V.N. (2001) Destabilization of tRNA3(Lys) from the primer-binding site of HIV-1 genome by anti-A loop polyamide nucleotide analog. Nucleic Acids Res. 29, 5099-5106.
17. KAUSHIK, N., BASU, A., PALUMBO, P., MYERS, R.L., and PANDEY, V.N. (2002a). Anti-TAR polyamide nucleotide analog conjugated with a membrane-permeating peptide inhibits human immunodeficiency virus type 1 production. J. Virol. 76, 3881-3891.
18. KAUSHIK, N., BASU, A., and PANDEY, V.N. (2002b). Inhibition of HIV-1 replication by anti-trans-activation responsive polyamide nucleotide analog. Antiviral Res. 56, 13-27.
19. KNUDSEN, H., and NIELSEN, P.E. (1997). Application of peptide nucleic acid in cancer therapy. Anticancer Drugs 8, 113-118.
20. KOPPELHUS, U., and NIELSEN, P.E. (2003). Cellular delivery of peptide nucleic acid (PNA). Advanced Drug Deliv. Rev. 55, 267-280.
21. LANGEL, U., and ZORKO, M. (2005). Cell-penetrating peptides: mechanism and kinetics of cargo delivery. Advanced Drug Deliv. Rev. 57, 529-545.
22. LEE, R., KAUSHIK, N., MODAK, M.J., VINAYAK, R., and PANDEY, V.N. (1998). Polyamide nucleic acid targeted to the primer binding site of the HIV-1 RNA genome blocks in vitro HIV-1 reverse transcription. Biochemistry 37, 900-910.
23. LETOHA, T., KUSZ, E., PÁPAI, G., SZABOLACS, A., KASKAZI, J., VARGA, T., TAKÁCS, T., PENKE, B., and DUDA, E. (2006). In vitro and in vivo nuclear factor-kappaB inhibitory effects of the cell-penetrating penetratin peptide. Mol. Pharmacol. 69, 2027-2036.
24. MAIER, M.A., ESAU, C.C., SIWKOWSKI, A.M., WANCEWICZ, E.V., ALBERTSHOFER, K., KINBERGER, G.A., KADABA, N.S., WATANABE, T., MANOHARAN, M., BENNETT, C. F., GRIFFEY, R.H., and SWAYZE, E.E. (2006). Evaluation of basic amphipathic peptides for cellular delivery of antisense peptide nucleic acids. J. Med. Chem. 49, 2534-2342.
25. MAYHOOD, T., KAUSHIK, N., PANDEY, P.K., KASHANCHI, F., DENG, L., and PANDEY, V.N. (2000). Inhibition of Tat-mediated transactivation of HIV-1 LTR transcription by polyamide nucleic acid targeted to TAR hairpin element. Biochemistry 39, 11532-11539.
26. MCMAHON, B.M., MAYS, D., LIPSKY, J., STEWART, J.A., FAUQ, A., and RICHELSON, E. (2002). Pharmacokinetics and tissue distribution of a peptide Nucleic acid after intravenous administration. Antisense Nucleic Acid Drug Dev. 12, 65-70.
27. NIELSEN, P.E., EGHOLM, M., BERG, R.H., and BUCHARDT, O. (1991). Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254, 1497-500.
28. PIERCE, T.L., WHITE, A.R., TREGEAR, G.W., and SEXTON, P.M. (2005). Peptide-oligonucleotide hybrids in antisense therapy. Mini. Rev. Med. Chem. 5, 41-55.
29. REMBACH, A., TURNER, B.J., BRUCE, S., CHEAH, I.K., SCOTT, R.L., LOPES, E.C., ZAGAMI, C.J., BEART, P.M., CHEUNG, N.S., LANGFORD, S.J., and CHEEMA, S.S. (2004). Antisense peptide nucleic acid targeting GluR3 delays disease onset and progression in the SOD1 G93A mouse model of familial ALS. J. Neurosci. Res. 77, 573-582.
30. SARMIENTO, U.M., PEREZ, J.R., BECKER, J.M., and NARAYANAN, R. (1994). In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice. Antisense Res Dev. 4, 99-107.
31. SAZANI, P., GEMIGNANI, F., KANG, S.H., MAIER, M.A., MANOHARAN, M., PERSMARK, M., BORTNER, D., and KOLE, R. (2002). Systemically delivered antisense oligomers upregulate gene expression in mouse tissues. Nat. Biotechnol. 20, 1228-1233.
32. TAN, X.X., ACTOR, J.K., and CHEN, Y. (2005). Peptide nucleic acid antisense oligomer as a therapeutic strategy against bacterial infection: proof of principle using mouse intraperitoneal infection. Antimicrob. Agents Chemother. 49, 3203-3207.
33. TRIPATHI, S., CHAUBEY, B., GANGULY, S., HARRIS, D., CASALE, R.A., and PANDEY, V.N. (2005). Anti-HIV-1 activity of anti-TAR polyamide nucleic acid conjugated with various membrane transducing peptides. Nucleic Acids Res. 33, 4345-4356.
34. TRIPATHI, S., CHAUBEY, B., BARTON, B.E. and PANDEY, V.N. (2007). Anti HIV-1 virucidal activity of polyamide nucleic acid-membrane transducing peptide conjugates targeted to primer binding site of HIV-1 genome. Virology 363, 91-103.
35. WALLACE, T.L., GAMBA-VITALO, C., LOVEDAY, K.S., and COSSUM, P.A. (2000). Acute, multiple-dose, and genetic toxicology of AR177, an anti-HIV oligonucleotide. Toxicol. Sci. 53, 63-70.